Heron Therapeutics, Inc.
US ˙ NasdaqCM ˙ US4277461020

SecurityHRTX / Heron Therapeutics, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership30,355 shares
Latest Disclosed Value $ 24,287
Qube Research & Technologies Ltd ownership in HRTX / Heron Therapeutics, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 30,355 shares of Heron Therapeutics, Inc. (US:HRTX) valued at $24,287 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2025 disclosing 0 shares of Heron Therapeutics, Inc.. The current value of the position is $12,974 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F HERON THERAPEUTICS COM 427746102 30,355 30,355 24 0.0000
2025-11-14 2025-09-30 13F HERON THERAPEUTICS COM 427746102 0 -132,782 -100.00 0 -100.00
2025-08-14 2025-06-30 13F HERON THERAPEUTICS COM 427746102 132,782 132,782 275 0.0003
2025-02-14 2024-12-31 13F HERON THERAPEUTICS COM 427746102 0 -1,146,658 -100.00 0 -100.00
2024-11-14 2024-09-30 13F HERON THERAPEUTICS COM 427746102 1,146,658 639,431 126.06 2,282 28.51 0.0034
2024-08-14 2024-06-30 13F HERON THERAPEUTICS COM 427746102 507,227 -54,757 -9.74 1,775 14.07 0.0028
2024-05-14 2024-03-31 13F HERON THERAPEUTICS COM 427746102 561,984 561,984 1,557 0.0025
2024-02-13 2023-12-31 13F HERON THERAPEUTICS COM 427746102 0 -6,021 -100.00 0 -100.00
2023-11-13 2023-09-30 13F HERON THERAPEUTICS COM 427746102 6,021 6,021 6 0.0000
2023-05-15 2023-03-31 13F HERON THERAPEUTICS COM 427746102 0 -502,756 -100.00 0 -100.00
2023-02-14 2022-12-31 13F HERON THERAPEUTICS COM 427746102 502,756 399,171 385.36 1,257 187.41 0.0067
2022-11-14 2022-09-30 13F HERON THERAPEUTICS COM 427746102 103,585 24,288 30.63 437 97.74 0.0026
2022-08-15 2022-06-30 13F HERON THERAPEUTICS COM 427746102 79,297 2,216 2.87 221 -49.89 0.0016
2022-05-09 2022-03-31 13F HERON THERAPEUTICS COM 427746102 77,081 77,081 441 0.0037
2020-08-14 2020-06-30 13F HERON THERAPEUTICS COM 427746102 0 -11,543 -100.00 0 -100.00
2020-05-15 2020-03-31 13F HERON THERAPEUTICS COM 427746102 11,543 -5,687 -33.01 136 -66.42 0.0056
2020-02-13 2019-12-31 13F HERON THERAPEUTICS COM 427746102 17,230 17,230 405 0.0127
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.